Study summary

A 4-month antibody course kept more people off treatment failure

VAYHIT2 trial (ianalumab) · 152 people, phase 3 · Published April 2026, New England Journal of Medicine

54%free of treatment failure at 12 months (9 mg), vs 30%

What was tested

Ianalumab, an antibody that depletes B cells and blocks the BAFF receptor, given monthly for 4 months, with eltrombopag, against placebo plus eltrombopag, after first-line steroids failed.

What they found

What it means

Could offer a short course instead of indefinite treatment.

N Engl J Med, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.